Large US market Krystal Biotech is a commercial-stage biotech with notable US revenue growth for VYJUVEK targeting dystrophic epidermolysis bullosa (DEB), presenting a clear near-term opportunity to expand payer engagement, access programs, and specialist physician partnerships in the United States.

Global expansion Reports of rising global sales of VYJUVEK and expanded treatment access overseas indicate a ripe opportunity to identify regional distributors, local CROs, and regulatory affairs partners to accelerate international commercialization and market penetration.

Pipeline potential Krystal is developing multiple pipeline products for other indications, signaling opportunities to propose translational collaborations, companion diagnostics, or strategic partnerships to diversify portfolio and open new addressable markets with existing distribution channels.

Strategic leadership Past leadership changes in commercial roles and ongoing shifts suggest a need for targeted business development support, channel optimization, and reorientation of market access strategies to maximize revenue capture from current and upcoming launches.

Financial health With substantial funding and observed revenue growth, there is a favorable environment for strategic partnerships and co-development deals, including potential out-licensing of non-core assets to accelerate pipeline value while maintaining core ownership.